Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Autism Clinical Trials

A listing of Autism medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (5) clinical trials

Evaluation of the Efficacy Safety and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

This is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of multiple doses of sarizotan in patients with Rett syndrome with respiratory abnormalities. The study participants will be randomized to either sarizotan between 2 and 10 mg bid or placebo bid, based on age and ...

Phase

A Trial of Metformin in Individuals With Fragile X Syndrome

This is a single-center study at the UC Davis MIND Institute for fragile X syndrome (FXS) patients aged 6 to 25 years inclusive. It is a randomized, double-blind, placebo-controlled trial of metformin (also known as Glumetza, Glucophage, Fortamet), a type 2 diabetes medication that can also improve obesity and excessive ...

Phase

Study of Acamprosate in Autism

Each subject with ASD will receive 10 weeks of blinded treatment with acamprosate or matching placebo. After completion of the double-blind phase, all subjects will have an opportunity to receive acamprosate as part of the study procedures for 16 weeks.

Phase

Testing a Novel Speech Intervention in Minimally Verbal Children With Autism Spectrum Disorder (ASD)

The ability to communicate verbally is considered the most important prognostic indicator for children with ASD. If a child has not developed speech by age 5, it is generally considered unlikely that he or she will do so. Although a small number of cases of speech development in older children ...

Phase

Study of Acamprosate in Fragile x Syndrome

Each subject with FXS will receive 10 weeks of blinded treatment with acamprosate or matching placebo. After completion of the double-blind phase, all subjects will have an opportunity to receive acamprosate as part of the study procedures for 16 weeks.

Phase